BiVictriX Therapeutics receives FDA orphan drug designation for BVX001 in AML
BiVictriX Therapeutics plc (AIM: BVX), a prominent UK-based biotechnology firm, has reached a pivotal regulatory milestone as the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead asset, BVX001. This designation is for the treatment of Acute Myeloid Leukaemia (AML), a critical area with substantial unmet medical needs. This […]